Synthaverse S.A. (WSE:SVE)

Poland flag Poland · Delayed Price · Currency is PLN
3.430
-0.010 (-0.29%)
Apr 28, 2026, 5:00 PM CET
-23.44%
Market Cap 242.74M
Revenue (ttm) 71.76M
Net Income (ttm) 7.55M
Shares Out 70.77M
EPS (ttm) n/a
PE Ratio 54.33
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,351
Average Volume 58,192
Open 3.440
Previous Close 3.440
Day's Range 3.375 - 3.490
52-Week Range 3.300 - 5.910
Beta 0.24
RSI 37.72
Earnings Date Apr 30, 2026

About Synthaverse

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1944
Employees 239
Stock Exchange Warsaw Stock Exchange
Ticker Symbol SVE
Full Company Profile

Financial Performance

In 2024, Synthaverse's revenue was 71.76 million, an increase of 22.44% compared to the previous year's 58.61 million. Earnings were 7.55 million, an increase of 58.68%.

Financial Statements

News

There is no news available yet.